Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma

Chest

Volumn 127, Issue 1, 2005, Pages 117-124

  Foresi, Antonio ^a,d   Mastropasqua, Berardino ^a   Chetta, Alfredo ^b   D'Ippolito, Raffaele ^b   Testi, Renato ^c   Olivieri, Dario ^b   Pelucchi, Andrea ^a  

^a Sesto San Giovanni Hospital   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c GSK   (Italy)

^d Servizio di Pneumologia e Fisiopatologia Respiratoria   (Italy)

Author keywords

Asthma; Fluticasone propionate; Inhaled steroids; Sputum eosinophils

Indexed keywords

FLUTICASONE PROPIONATE; METHACHOLINE; PLACEBO; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; FLUTICASONE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; ADOLESCENT; CELL COUNT; COMPARATIVE STUDY; CYTOLOGY; INHALATION TEST; MIDDLE AGED; SPUTUM; VITAL CAPACITY;

ADOLESCENT; ADULT; ANDROSTADIENES; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; CELL COUNT; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; SPUTUM; VITAL CAPACITY;

EID: 13844322153     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.1.117     Document Type: Article

References (35)

1. British Thoracic Society. British guideline on the management of asthma. Thorax 2003; 58:1-94
2. Postma DS, Kerstjens HA. Characteristics of airway hyperresponsiveness in asthma and in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:S187-S192
3. Chetta A, Gerra G, Foresi A, et al. Personality profiles and breathlessness perception in outpatients with different gradings of asthma. Am J Respir Crit Care Med 1998; 157: 116-122
4. Rosi E, Ronchi MC, Grazzini M, et al. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999; 103:232-237
5. Parameswaran K, Hargreave FE. The use of sputum cell counts to evaluate asthma medications. Br J Clin Pharmacol 2001; 52:121-128
6. Fahy JV, Boushey HA. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. Eur Respir J 1998; 11:1240-1247
7. Gershman NH, Wong HH, Liu JT, et al. Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000; 15:11-18
8. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-412
9. van der Molen T, Kerstjens HA. Starting inhaled corticosteroids in asthma: when, how high, and how long. Eur Respir J 2000; 15:3-4
10. van der Molen T, Meyboom-De Jong B, Mulder HH, et al. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. Am J Respir Crit Care Med 1998; 158:121-125
11. Tukiainen H, Taivainen A, Majander R, et al. Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir Med 2000; 94:678-683
12. Nathan RA, Li JTC, Finn A, et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118:296-302
13. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pneumol 2000; 29:415-423
14. Visser MJ, Postma DS, Arends LR, et al. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma: effects on hyperresponsiveness, lung function, and height. Am J Respir Crit Care Med 2001; 164:2073-2077
15. Global strategy for asthma management and prevention, updated April, 2002. Bethesda, MD: National Institutes of Health, 2002; publication No. 02-3659
16. Bacharier L. "Step-down" therapy for asthma: why, when, and how? J Allergy Clin Immunol 2002; 109:916-919
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 153:S77-121
18. Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56:323-327
19. Fahy JV, Liu J, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147:1126-1131
20. Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161:475-478
21. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243
22. Jatakanon A, Kharitonov S, Lim S, et al. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54:108-114
23. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001
24. Chetta A, Foresi A, Del Donno M, et al. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111:852-857
25. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72
26. Belda J, Giner J, Casan P, et al. Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. Chest 2001; 119:1011-1017
27. Green RH, Brighting CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721
28. Convery RP, Leitch DN, Bromly C, et al. Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naive individuals: a lesser benefit in females. Eur Respir J 2000; 15:19-24
29. Chervinsky P, van As A, Bronsky E, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94:676-683
30. Busse W, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101:457-461
31. Giannini D, Di Franco A, Cianchetti S, et al. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. Clin Exp Allergy 2000; 30:1777-1784
32. in't Veen JC, Smits HH, Hiemstra PS, et al. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 1999; 160:93-99
33. Szefler S, Martin R, King T, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418
34. Bisgaard H, Gillies J, Groenewald M, et al. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999; 160:126-131
35. Chetta A, Zanini A, Foresi A, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003; 167:751-757